BestStocksBeta
Market open · Delayed intraday data · 1:59 PM ET
Last update: Nov 2, 2026, 1:52 PM ET
Krystal Biotech, Inc.
$285.68▼ 14.03% today
Market Open

Why Krystal Biotech, Inc. (KRYS) stock moved

Updated Nov 2, 2026

Krystal Biotech, Inc. (KRYS) shares tumbled 14.0% to $285.68 as of November 2, 2026, a sharp decline from the prior close of $332.29. BestStocks flagged the session as a major change for KRYS. The move is tied to an earnings beat. Below, we break down what changed for KRYS, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

Earnings Beat

Krystal Biotech, Inc. (KRYS) reported Q3 FY2026 EPS of $2.05 vs. consensus estimate of $1.79, beating by 14.5% on 2026-11-02. Monitor KRYS's next quarterly earnings report and any updates on clinical trial progress or regulatory developments for its pipeline programs.

This summary describes the catalyst and move as first detected on Nov 2, 2026, 10:08 AM EST; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
Material / EarningsHigh confidence
Rel. volume
1.9×
Above Avg
Vs peers
—
No comparable peers
Market cap
$8.5B
NASDAQ Global Market
Analyst target
$395
+38.3% vs price
Price chart
Oct 2 – Nov 2
VENNVNENNFEN$285$310$336Oct 2Oct 9Oct 19Oct 26Nov 2
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Krystal Biotech, Inc. investors

For Krystal Biotech, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Earnings beat — stock sold off (sell-the-news reaction). Weighing against that: Sharp 14.0% decline — elevated risk; Krystal Biotech reported third-quarter 2026 financial and operating results today (Globe Newswire), triggering a 14.1% intraday decline from $332.29 to $285.44. Wall Street's consensus price target sits at $395.20, implying +38.3% upside from $285.68. BestStocks rates the overall signal quality high (81/100). With earnings due imminently, the next report is the most likely near-term test of the move.

KRYS price reaction

KRYS last traded at $285.68, down $46.61 (-14.03%) from the previous close of $332.29. The session traded on 1.9× average volume (above avg), so the move carried above-average conviction. Over the past month the stock has ranged between $285.68 and $334.85, and it currently sits about 0% of the way up that band.

Bullish and bearish analyst opinions on Krystal Biotech, Inc. (KRYS)

Latest catalysta mixed signal
The latest catalyst — an earnings beat the stock sold off — it cuts both ways, with the event and the market's reaction pointing in different directions.

The consensus analyst price target on Krystal Biotech, Inc. (KRYS) is $395.20, 38.3% above the recent $285.68. Over the past 90 days analysts logged 0 upgrades, 3 maintains, and 0 downgrades. Here is how the bullish and bearish cases on KRYS line up.

The bullish case

  • Wall Street's consensus price target of $395.20 implies +38.3% upside from $285.68.
  • The Street's most bullish target is $474.00 (+65.9%).
  • Earnings beat — stock sold off (sell-the-news reaction).

The bearish case

  • Sharp 14.0% decline — elevated risk.
  • Krystal Biotech reported third-quarter 2026 financial and operating results today (Globe Newswire), triggering a 14.1% intraday decline from $332.29 to $285.44.
  • Krystal Biotech filed a material event (Form 8-K) today, triggering a 2.73% intraday decline to $321.00.
  • Krystal Biotech shares fell 6.42% to $343.30, with volume running at 0.56x the historical average for this time of day.
Bull vs bear balanceBearish Shift
BearishNeutralBullish
The latest catalyst moved the balance toward the bulls — the hollow tick marks where it sat before.

Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Nov 2, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $395+38.3%
= 3 maintains
HC Wainwright & Co. maintained Buy · 2026-10-15
SEC filings watch
8-K2026-10-15
Material event — review for impact
high
8-K2026-08-03
Material event — review for impact
high
10-Q2026-08-03
Quarterly financial results
medium
8-K2026-07-21
Material event — review for impact
high
Peer context
KRYS-14.0%

Previous notable changes for KRYS

Risk2026-11-02-14.0%via globenewswire.com ↗
Krystal Biotech reported third-quarter 2026 financial and operating results today (Globe Newswire), triggering a 14.1% intraday decline from $332.29 to $285.44. Volume surged to 7.7x the time-adjusted average at 322,889 shares in the first 60 minutes, indicating heavy selling pressure tied to the earnings announcement.
News2026-11-02-14.0%
KRYS reports $127.3M quarterly VYJUVEK revenue with $1.1B cumulative sales and KB113 showing 80% lesion regression.
Material / Earnings2026-10-27+2.2%
Krystal Biotech, Inc. (KRYS) moved +2.93% from $311.45 to $320.58 on 2026-10-27. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move occurred on volume near its 5-day average.
News2026-10-26+0.7%
Analysts project KRYS will miss earnings expectations due to lacking key performance drivers.
Upcoming catalysts & outlook
Next earnings
2026-11-02
in 0 days
Thesis shift
Bearish Shift
bearish signal
Risk level
High
from change events

Frequently asked questions about KRYS

Why did Krystal Biotech, Inc. (KRYS) stock move?

KRYS tumbled 14.0% to $285.68. The move is associated with an earnings beat.

How much did KRYS stock fall?

KRYS lost 14.03% ($46.61) versus the prior close of $332.29, last trading at $285.68 on 1.9× average volume.

When is Krystal Biotech, Inc.'s next earnings date?

KRYS's next earnings report is scheduled for 2026-11-02 — about 0 days away.

What is the analyst price target for KRYS?

The consensus analyst price target for KRYS is $395.20, about 38.3% above the current $285.68. Over the past 90 days, analysts recorded 0 upgrades, 3 maintains, and 0 downgrades.

How BestStocks tracks KRYS

This page is generated automatically by BestStocks' change-detection system after an earnings beat was detected and verified against independent data sources. It draws on 20 tracked change events for KRYS, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 2, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataFMP earnings & estimatesCompany news feedsSEC EDGAR filingsAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.